DBV Technologies (NASDAQ: DBVT) and Trinity Biotech PLC (NASDAQ:TRIB) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations and institutional ownership.
Valuation and Earnings
This table compares DBV Technologies and Trinity Biotech PLC’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|DBV Technologies||$11.21 million||178.79||-$160.53 million||N/A||N/A|
|Trinity Biotech PLC||$98.79 million||1.21||$7.39 million||($3.66)||-1.49|
Trinity Biotech PLC has higher revenue and earnings than DBV Technologies.
This is a summary of recent ratings and target prices for DBV Technologies and Trinity Biotech PLC, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Trinity Biotech PLC||0||1||0||0||2.00|
DBV Technologies currently has a consensus price target of $48.80, indicating a potential upside of 12.00%. Given DBV Technologies’ stronger consensus rating and higher possible upside, equities analysts plainly believe DBV Technologies is more favorable than Trinity Biotech PLC.
Institutional and Insider Ownership
48.6% of DBV Technologies shares are held by institutional investors. Comparatively, 64.4% of Trinity Biotech PLC shares are held by institutional investors. 15.3% of DBV Technologies shares are held by company insiders. Comparatively, 12.7% of Trinity Biotech PLC shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Risk and Volatility
DBV Technologies has a beta of 1.53, meaning that its stock price is 53% more volatile than the S&P 500. Comparatively, Trinity Biotech PLC has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500.
This table compares DBV Technologies and Trinity Biotech PLC’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Trinity Biotech PLC||-100.45%||5.54%||2.70%|
DBV Technologies beats Trinity Biotech PLC on 7 of the 12 factors compared between the two stocks.
DBV Technologies Company Profile
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company’s product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.
Trinity Biotech PLC Company Profile
Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company’s products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine. It operates through two segments: the Americas and Rest of World. Its products are classified as POC, emergency medicine, clinical laboratory and blood bank screening. Its POC brands include Uni-Gold and Recombigen. Emergency medicine diagnostics refer to its acute care testing, STAT labs, pre/post-operative units, physician office labs and the central laboratory. Trinity Biotech supplies clinical laboratory market with reagent products and other products through its clinical chemistry business. Trinity Biotech’s blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections.
Receive News & Ratings for DBV Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies S.A. and related companies with MarketBeat.com's FREE daily email newsletter.